DurchfallWe have been broken through the low of October/November 2023. In January we did not succeed yet but now we have managed to. Hopefully we can remain under this support until the end of February. But anyway the break is a short signal and the present attempt to retrace upward may be seen as healthy pr
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
5.89 MXN
214.69 M MXN
84.44 B MXN
48.56 M
About Charles River Laboratories International, Inc.
Sector
CEO
James C. Foster
Website
Headquarters
Wilmington
Founded
1947
FIGI
BBG013GN0YZ1
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The Discovery and Safety Assessment segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.
CRL: bullish megaphone patternA bullish trend is applicable above 206.00
Further bullish confirmation for a break above 216.00
The target price is set at 224.00.
The stop-loss price is set at 202.00.
An incomplete bullish megaphone pattern is busy developing.
Furthermore testing its 200-day simple moving average as well as its 2
Charles River Labs is Leaking and now Sinking. CRLWe are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statisti
CRL offering an early entry with a pocket pivot?* Exceptional earnings
* Very strong up trend
* High RS in the Healthcare industry
* Pocket pivot occurring on the right side of a rounded constructive basing pattern
Trade Idea:
* You can get in now as indicated
* Or if you're looking for a slight discount you can look for an entry near the $423.6
CRL Short PredictionA very short prediction for CRL.............................................................................................................................................................................................................................................................................
Charles River Laboratories Q2 Profit, Revenue RiseStock suggested by my dad as one to watch. Nice strong upward trend with financials also headed in the right way.
Might be a bit expensive at the moment looking at the RSI, so on the watch list waiting for a bit of a pullback prior to any entry decisions.
Worth a look.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
CRL5145816
Charles River Laboratories International, Inc. 4.0% 15-MAR-2031Yield to maturity
7.83%
Maturity date
Mar 15, 2031
CRL5145814
Charles River Laboratories International, Inc. 3.75% 15-MAR-2029Yield to maturity
7.47%
Maturity date
Mar 15, 2029
CRL4900987
Charles River Laboratories International, Inc. 4.25% 01-MAY-2028Yield to maturity
7.41%
Maturity date
May 1, 2028
CRL4900988
Charles River Laboratories International, Inc. 4.25% 01-MAY-2028Yield to maturity
—
Maturity date
May 1, 2028
See all CRL bonds
Related stocks
Frequently Asked Questions
The current price of CRL is 2,972.17 MXN — it has decreased by −3.59% in the past 24 hours. Watch CHARLES RIVER LABORATORIES stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange CHARLES RIVER LABORATORIES stocks are traded under the ticker CRL.
CRL stock has fallen by −3.59% compared to the previous week, the month change is a −3.59% fall, over the last year CHARLES RIVER LABORATORIES has showed a −29.94% decrease.
We've gathered analysts' opinions on CHARLES RIVER LABORATORIES future price: according to them, CRL price has a max estimate of 3,781.17 MXN and a min estimate of 1,407.88 MXN. Watch CRL chart and read a more detailed CHARLES RIVER LABORATORIES stock forecast: see what analysts think of CHARLES RIVER LABORATORIES and suggest that you do with its stocks.
CRL stock is 3.72% volatile and has beta coefficient of 0.34. Track CHARLES RIVER LABORATORIES stock price on the chart and check out the list of the most volatile stocks — is CHARLES RIVER LABORATORIES there?
Today CHARLES RIVER LABORATORIES has the market capitalization of 105.30 B, it has decreased by −7.26% over the last week.
Yes, you can track CHARLES RIVER LABORATORIES financials in yearly and quarterly reports right on TradingView.
CHARLES RIVER LABORATORIES is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
CRL earnings for the last quarter are 55.46 MXN per share, whereas the estimation was 52.70 MXN resulting in a 5.24% surprise. The estimated earnings for the next quarter are 42.50 MXN per share. See more details about CHARLES RIVER LABORATORIES earnings.
CHARLES RIVER LABORATORIES revenue for the last quarter amounts to 20.90 B MXN, despite the estimated figure of 20.51 B MXN. In the next quarter, revenue is expected to reach 19.30 B MXN.
CRL net income for the last quarter is −4.50 B MXN, while the quarter before that showed 1.35 B MXN of net income which accounts for −432.33% change. Track more CHARLES RIVER LABORATORIES financial stats to get the full picture.
No, CRL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 20.1 K employees. See our rating of the largest employees — is CHARLES RIVER LABORATORIES on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CHARLES RIVER LABORATORIES EBITDA is 19.20 B MXN, and current EBITDA margin is 22.93%. See more stats in CHARLES RIVER LABORATORIES financial statements.
Like other stocks, CRL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CHARLES RIVER LABORATORIES stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CHARLES RIVER LABORATORIES technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CHARLES RIVER LABORATORIES stock shows the strong sell signal. See more of CHARLES RIVER LABORATORIES technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.